Clinical Trials
3 trialsNCT07551544 2026-05-19
ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer
ImmunityBio, Inc.
Phase 3 Withdrawn
NCT07313891 2026-03-17
BOOST
Relmada Therapeutics, Inc.
Phase 3 Withdrawn
NCT06816017 2025-06-16
A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Hoffmann-La Roche
Phase 1 Withdrawn